Nivolumab
BMS
['melsm', 'melanoma']
randomisation of high-risk melanoma to placebo with pd1 stage2 approved? surely there s an issue .#melsm #asco2023 
#Melanoma patient advocate, MD/PhD, in want of patient-centred research. Member of the first EU Cancer Mission Board. Views are totally my own.